

Phase 3 study of precentabart tocentecan (Precem-TcT) with or without bevacizumab compared to trifluridine/tipiracil (FTD-TPI) plus bevacizumab in participants with previously treated metastatic colorectal cancer



Study Schema

Screening Period
Up to 28 days









Study Treatment Period

Participants will be randomized in a 1:1:1 ratio to 1 of 3 open-label treatment groups.

Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, any criterion for treatment discontinuation, or death, whatever comes first.



Arm	Single-agent Precem-TcT	Precem-TcT + Standard of Care	Combination Standard of Care
Cycle length	3 weeks	3 weeks	4 weeks
Study treatment	 Precem-TcT on Day 1	 Precem-TcT on Day 1  Bevacizumab on Day 1	 Oral FTD-TPI on Days 1 to 5 and Days 8 to 12  Bevacizumab on Day 1 and Day 15
Visit frequency	Cycle 1: Day 1, 8, 15	Cycle 1: Day 1, 8, 15	Cycle 1: Day 1, 8, 15
	Cycles 2–6: Day 1, 15	Cycles 2–6: Day 1, 15	Cycles 2+: Day 1, 15
	Cycles 7+: Day 1	Cycles 7+: Day 1	
Tumor scans	 After screening scans, tumor scans will be done every 6 weeks for 6 times, then every 12 weeks.		



Safety Follow-up Period
30 days after last dose



Long-Term Follow-up Period (Survival Follow-up)
Phone call, video call, or visit every 90 days



Scan the code or visit
proceadecrc03study.com.

PIN: 9140